Trial Profile
A Randomised, Double-blind, Placebo-controlled, Trial to Compare the Safety and Efficacy of Reduced Dose Versus Standard Dose EFV Plus Two Nucleotides (N(t)RTI) in Antiretroviral-naïve HIV-infected Adults Over 96 Weeks
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Efavirenz (Primary) ; Emtricitabine/tenofovir disoproxil fumarate
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms ENCORE1
- 18 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 10 Feb 2014 Results at 48 weeks published in the Lancet online
- 03 Jul 2013 Primary endpoint 'Virological-response-rate' has been met according to results presented at the 7th International AIDS Society Conference on HIV Pathogenesis and Treatment.